CREBBP and neoplasm: APC (p = 1.7e-20), BCL9 (p = 0.0006), CREBBP (p = 8.5e−5), FLCN (p = 1.39e−7), NSD2 (p = 0.002), and EP300 (p = 1.42e−6) all had significantly higher mutation rates in MSLN low expressing tumor samples compared to MSLN high expressing tumor samples (Fig. 2A).